Genetic drugs based on nucleic acid biomolecules are a rapidly emerging class of
medicines that directly reprogramme the central dogma of biology to prevent and treat …

RNA-based gene therapy requires therapeutic RNA to function inside target cells without
eliciting unwanted immune responses. RNA can be ferried into cells using non-viral drug …

Ionizable lipid nanoparticles (LNPs) are the most clinically advanced nonviral platform for
mRNA delivery. While they have been explored for applications including vaccines and …

Cancer nanomedicines were initially envisioned as magic bullets, travelling through the
circulation to target tumours while sparing healthy tissues the toxicity of classic …

Lipid nanoparticles (LNPs) for the efficient delivery of drugs need to be designed for the
particular administration route and type of drug. Here we report the design of LNPs for the …

Abstract mRNA vaccines have evolved from being a mere curiosity to emerging as COVID-
19 vaccine front-runners. Recent advancements in the field of RNA technology, vaccinology …

CRISPR-based drugs can theoretically manipulate any genetic target. In practice, however,
these drugs must enter the desired cell without eliciting an unwanted immune response, so …

In humans, lipid nanoparticles (LNPs) have safely delivered therapeutic RNA to hepatocytes
after systemic administration and to antigen-presenting cells after intramuscular injection …

Extracellular vesicles (EVs) carry diverse bioactive components including nucleic acids,
proteins, lipids and metabolites that play versatile roles in intercellular and interorgan …

Lipid nanoparticles (LNPs) are the leading nonviral technologies for the delivery of
exogenous RNA to target cells in vivo. As systemic delivery platforms, these technologies …